Abstract
The rationale for surfactant replacement therapy in patients with acute respiratory distress syndrome (ARDS) is to restore the normal composition of the surfactant system, as well as to overcome ongoing inactivation of present surfactant. Indeed, surfactant replacement therapy can normalize the composition of the surfactant system and restore its surface activity, which results in restoration of the gas exchange. Several phase II- and phase III-studies have been performed to investigate safety and efficacy of surfactant replacement therapy in patients with ARDS. In this manuscript we will discuss the differences in the composition of exogenous surfactant, the diverse modes of delivery of surfactant, and timing of therapy, in relation to the efficacy of surfactant instillation in several published and yet unpublished studies.
Keywords: Additive Drug, ARDS-Patients, exogenous surfactant
Current Drug Targets
Title: Is Surfactant a Promising Additive Drug in ALI / ARDS-Patients?
Volume: 5 Issue: 5
Author(s): Marcus J. Schultz and Jozef Kesecioglu
Affiliation:
Keywords: Additive Drug, ARDS-Patients, exogenous surfactant
Abstract: The rationale for surfactant replacement therapy in patients with acute respiratory distress syndrome (ARDS) is to restore the normal composition of the surfactant system, as well as to overcome ongoing inactivation of present surfactant. Indeed, surfactant replacement therapy can normalize the composition of the surfactant system and restore its surface activity, which results in restoration of the gas exchange. Several phase II- and phase III-studies have been performed to investigate safety and efficacy of surfactant replacement therapy in patients with ARDS. In this manuscript we will discuss the differences in the composition of exogenous surfactant, the diverse modes of delivery of surfactant, and timing of therapy, in relation to the efficacy of surfactant instillation in several published and yet unpublished studies.
Export Options
About this article
Cite this article as:
Schultz J. Marcus and Kesecioglu Jozef, Is Surfactant a Promising Additive Drug in ALI / ARDS-Patients?, Current Drug Targets 2004; 5 (5) . https://dx.doi.org/10.2174/1389450043345399
DOI https://dx.doi.org/10.2174/1389450043345399 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Caffeic Acid Phenethyl Ester: A Potential Anticancer Bioactive Constituent
of Propolis
Current Cancer Therapy Reviews Improved Prediction of Protein Ligand-Binding Sites Using Random Forests
Protein & Peptide Letters Hybrid Imaging in Evaluation of Abdominal Sarcoidosis
Current Medical Imaging Defining Carbohydrate Antigens as HIV Vaccine Candidates
Current Pharmaceutical Design Nanotechnology-based Approaches for COVID-19: A Path Forward
Current Nanomaterials Cardiac Metabolism in Myocardial Ischemia
Current Pharmaceutical Design MiR-223-3p Aggravates Ocular Inflammation in Sjögren’s Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Decision Tree Methods in Pharmaceutical Research
Current Topics in Medicinal Chemistry Neuroprotection of Coenzyme Q10 in Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Link of COVID-19 and Neurodegenerative Disorders
CNS & Neurological Disorders - Drug Targets Assessment of the Antineoplastic Potential of Chalcones in Animal Models
Current Medicinal Chemistry Review of the Phytochemistry and Biological Activity of Cissus incisa Leaves
Current Topics in Medicinal Chemistry Vitamin D and Acute Respiratory Tract Infection
Current Respiratory Medicine Reviews CFTR Inhibitors
Current Pharmaceutical Design Impact of COVID-19 on Indian Pharmaceutical Industry and Way Forward
Infectious Disorders - Drug Targets Development of 11β -HSD1 Inhibitors for the Treatment of Type 2 Diabetes
Mini-Reviews in Medicinal Chemistry Tranexamic Acid and Plasminogen/Plasmin Glaring Paradox in COVID-19
Endocrine, Metabolic & Immune Disorders - Drug Targets Chem-Bioinformatics : Computational Modeling of TIBO Derivatives
Anti-Infective Agents in Medicinal Chemistry Fate of Ionic Liquids in Soils and Sediments
Current Organic Chemistry Leptin, Immune Responses and Autoimmune Disease. Perspectives on the Use of Leptin Antagonists
Current Pharmaceutical Design